14576-66-0

Basic information

• Product Name: Decyldichlorophosphine oxide
• Synonyms: Decyldichlorophosphine oxide;Decylphoshonoyl chloride
• CAS NO: 14576-66-0
• Molecular Formula: C₁₀H₂₁Cl₂OP
• Molecular Weight: 259.15
• Mol File: 14576-66-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Decyldichlorophosphine oxide(CAS DataBase Reference)
• NIST Chemistry Reference: Decyldichlorophosphine oxide(14576-66-0)
• EPA Substance Registry System: Decyldichlorophosphine oxide(14576-66-0)

Safety Data

• Hazardous Substances Data: 14576-66-0(Hazardous Substances Data)

Upstream product

• 112-30-1 1-Decanol 
• 6874-60-8 1-decylphosphonic acid 
• 79-37-8 oxalyl dichloride 
• 16165-49-4 P-decylphosphonic acid, ethyl ester 
• 76964-69-7 decyl-phosphonic acid dimethyl ester 

Downstream Products

• 21612-77-1 Decylphosphonsaeure-bis-<4-nitro-phenylester> 
• 4762-28-1 diphenyldecylphosphine oxide 
• 21612-75-9 Decylphosphonsaeure-diphenylester 
• 60147-47-9 2-Decyl-2-oxo-1,3-dioxa-6-(β-oxyethyl)aza-2-phosphacyclooctane 
• 620623-28-1 C₇₀H₈₆F₆N₅O₁₅P 
• 21612-78-2 Decylphosphonsaeure-dicyclohexylester 
• 21612-76-0 Decylphosphonsaeure-bis-<2-nitro-phenylester> 

Relevant articles and documents

Inhibition of human gastric and pancreatic lipases by chiral alkylphosphonates. A kinetic study with 1,2-didecanoyl-sn-glycerol monolayer

Enantiomerically pure alkylphosphonate compounds RR'P(O)PNP (R=C(n)H(2n+1), R'=OY with Y=C(n')H(2n'+1) with n=n' or n≠n'; PNP=p-nitrophenoxy) noted (RY), mimicking the transition state occurring during the carboxyester hydrolysis were synthesized and investigated as potential inhibitors of human gastric lipase (HGL) and human pancreatic lipase (HPL). The inhibitory properties of each enantiomer have been tested with the monomolecular films technique in addition to an enyzme linked immunosorbent assay (ELISA) in order to estimate simultaneously the residual enzymatic activity as well as the interfacial lipase binding. With both lipases, no obvious correlation between the inhibitor molar fraction (α50) leading to half inhibition, and the chain length, R or Y was observed. (R11Y16)s were the best inhibitor of HPL and (R10Y11)s were the best inhibitors of HGL. We observed a highly enantioselective discrimination, both with the pure enantiomeric alkylphosphonate inhibitors as well as a scalemic mixture. We also showed, for the first time, that this enantioselective recognition can occur either during the catalytic step or during the initial interfacial adsorption step of the lipases. These experimental results were analyzed with two kinetic models of covalent as well as pseudo-competitive inhibition of lipolytic enzymes by two enantiomeric inhibitors. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents

Novel phosphorus containing compounds are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment of hypercholesterolemia and atherosclerosis.